PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE no persons are regulired to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwork Redu

(use as many sheets as necessary)

2 Sheet

Y	Complete if Known 09/606,433 June 28, 2000 Lawrence R. McGee et al. 1614 Linessigned	
Application Number	09/606,433	
Filing Date	June 28, 2000	以下し
First Named Inventor	Lawrence R. McGee et al.	
Group Art Unit	1614	400
Examiner Name	Unassigned	BrK .

18781-002710

U.S. PATENT DOCUMENTS					
		U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,
Examiner Initials *	Cite No. ¹	Number Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
MAA		5,093,340	Mohrs et al.	03/03/92	
AB					

Attorney Docket Number

				FOREIGI	N PATENT DOCU	MENTS		
Examiner Cite No.1	Foreign Patent Document		Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant			
	Office ³		nd Code ⁵ f <i>known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵	
DAY AC		EP	0 855 391 A1			8/7/97		
AD		EP	0 749 751 A2			6/20/96		
AE		EP	0 261 539 A2			3/30/88		
AF		EP	069 585 A1			1/12/83		.,
Same AG		wo	95/01326 ,			1/12/95		
AH		wo	96/15118			5/23/96		
AI		wo	99/06378			2/11/99		
AJ		wo	99/10320			3/4/99		
AK	1	wo	97/31907			9/4/97		
AL		wo	99/38845			213/65		<u> </u>
AM		EP	0778 267 A1	-		11/6/96		
ON AN		DE	€07D-213/24	DE	3632329	3/31/88		

Examiner	Ocaslo	Date 1/2= /ca 1	
Signature	Mylaman	Considered ((/ 2 1/0)	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.





Please type a plus sign (+) inside this box

Substitute for form 1449B/PTO

PTO/SB/08B (08-00) Approved for use through 10/31/2002. OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PADEMARY U.S. Patent and Trademark Office: U.S. DEFARTIVE IT OF CONTROL OF STREET OF CONTROL OF STREET OF CONTROL OF CONT Under the Paperwork Reduction Act of 1995, no persons

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/606,433 June 28, 2000 **Filing Date First Named Inventor** Lawrence R. McGee et al. Group Art Unit 1614 Examiner Name

(use as many sheets as necessary)

Sheet

Unassigned 18781-002710

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials_*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published,	
ON THE		LEHMANN et al., "Peroxisome Proliferator-activated Receptors α and γ Are Activated (1997) Indomethacin and Other Non-steroidal Anti-inflammatory Drugs," The Journal of Biological Chemistry, (1997) 272(6):3406-3410	
AP		WILSON et al., "The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones," J. Med. Chem., (1996), 9:665-668	
AQ		FORMAN et al., "75-Deoxy-Δ ^{12, 14} -Prostaglandin J₂ Is a Ligand for the Adipocyte Determination Factor PPARγ," Cell, (1995) 83;803-812	
AR		BURMISTROV et al., Database accessión no. 122:132338, Database Chemabs 'Online!, RN 134284-40-5 CAPLUS, Zh. Org. Khim, (1994) 30/6:744-747	
AS		SEBE et al., Database accession no. 117:214517, Database Chemabs 'Online!, RNs 144206-02-0 CAPLUS, 144232-65-5 CAPLUS, Rev. Chim, (1992).43(5-6):222-225	
AT		BURMISTROV et al., Database accession no. 115:8165, Database Chemabs 'Online!, RNs 98187-76-9 CAPLUS, 134284-40-5 CAPLUS, Zh. Org. Khim, (1990):26(9):1995-1998	
AU		PIEPER et al., Database accession no. 112:138679, Database Chemabs 'Online!, RN 101513-48-8 CAPLUS, ArzneimForsch., (1989) 39(9):1073-1080	
AV	_	BAGULEY et al., Database accession no. 108:179602, Database Chemabs 'Online!, RN 106831-10-1 CAPLUS, Eur. J. Cancer Clin. Oncol., (1988) 24(2):205-210	
→ AW		SARUL, et al., Database accession no. 103:123106, Database Chemabs 'Online!, RN 98187-77-0 CAPLUS, Latv. Psr Zinat. Akad. Vestis, Kim. Ser., (1985) 2:225-228	
AX		WOLLWEBER et al., Database accession no. 101:151540, Database Chemabs 'Online!, RN 92114-63-1 CAPLUS, ArzneimForsch., (1984):34(5):531-542	
AY		DENNY et al., Database accession no 496:79437, Database Chemabs 'Online!, RNs 80260-24-8 CAPLUS, 80260-26-0 CAPLUS, J. Med. Chem., (1982) 25(3):276-315	
AZ		MYSYK et al., Database accession no. 92:163637, Database Chemabs 'Online!, RN 73320-75-9 CAPLUS, Zh. Org. Khim, (1979) 15(12):2499-2502	
M		ZAITSEVA et al., Database accession no. 86:43377, Database Chemabs 'Online!, RN 61381-98-4 CAPLUS, Zh. Org. Khim, (1976) 12(9):1987-1992	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1208385 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.